Prevalence of chronic kidney disease in patients with psoriasis: place of genetic engineering biological therapy

Psoriasis is a common chronic immune-mediated disease that causes a significant burden on 125 million people worldwide. A growing body of research has led to the recognition that psoriasis is often associated with other conditions beyond the skin. Much research into the comorbidity of psoriasis has focused on the association with cardiovascular disease, cancer, infections, and psychiatric disorders, and recently there have been increasing reports of a correlation between psoriasis and kidney damage. Repeated studies have found an increased prevalence of microalbuminuria and renal failure in patients with psoriasis, and there has been a direct and inverse correlation between psoriasis, chronic kidney disease (CKD), and renal failure. Mechanisms of kidney damage may be immune-mediated, non-immune, or drug-related. The incidence, prevalence, and progression of CKD vary by race and social determinants of health, it affects ~11% of the population, and people with CKD are 5 to 10 times more likely to die prematurely than before progression to end-stage renal disease (ESRD). Additionally, psoriasis severity was associated with an increased risk of CKD and ESRD. Also, the risks of kidney damage increased in patients with other comorbid conditions (for example, psoriatic arthritis, diabetes mellitus, hypertension), which reflects the general background of systemic inflammation. In patients with psoriasis in the pediatric population, the relationship between psoriasis and kidney disease has not yet been proven.